XENCOR INC.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
$1B
Website

Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer

First Posted Date
2020-10-19
Last Posted Date
2023-04-20
Lead Sponsor
Xencor, Inc.
Target Recruit Count
4
Registration Number
NCT04590781
Locations
🇺🇸

OU Health, Stephenson Cancer Center, Oklahoma City, Oklahoma, United States

🇺🇸

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States

🇺🇸

Memorial Sloan Kettering, New York, New York, United States

and more 4 locations

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

First Posted Date
2019-02-21
Last Posted Date
2023-03-30
Lead Sponsor
Xencor, Inc.
Target Recruit Count
78
Registration Number
NCT03849469
Locations
🇺🇸

Emory University Hospital Midtown, Atlanta, Georgia, United States

🇺🇸

Winship Cancer Institute, Emory University, Atlanta, Georgia, United States

🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 25 locations

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

First Posted Date
2018-11-26
Last Posted Date
2024-07-05
Lead Sponsor
Xencor, Inc.
Target Recruit Count
198
Registration Number
NCT03752398
Locations
🇺🇸

Florida Cancer Specialists, Sarasota, Florida, United States

🇺🇸

Seattle Cancer Care Alliance, Seattle, Washington, United States

🇺🇸

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 15 locations

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

First Posted Date
2018-05-07
Last Posted Date
2022-12-01
Lead Sponsor
Xencor, Inc.
Target Recruit Count
150
Registration Number
NCT03517488
Locations
🇺🇸

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States

🇺🇸

UCLA Hematology-Oncology Clinic (Westwood), Los Angeles, California, United States

🇺🇸

University of California San Diego Moores Cancer Center, San Diego, California, United States

and more 14 locations

Study Evaluating AMG 424 in Subjects With Multiple Myeloma

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2018-02-26
Last Posted Date
2023-03-07
Lead Sponsor
Xencor, Inc.
Target Recruit Count
27
Registration Number
NCT03445663
Locations
🇦🇺

Research Site, Fitzroy, Victoria, Australia

A Study of XmAb®18087 in Subjects With NET and GIST

First Posted Date
2018-01-26
Last Posted Date
2022-05-10
Lead Sponsor
Xencor, Inc.
Target Recruit Count
62
Registration Number
NCT03411915
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

🇺🇸

City of Hope Medical Center, Duarte, California, United States

🇺🇸

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States

and more 11 locations

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

First Posted Date
2016-10-05
Last Posted Date
2024-11-13
Lead Sponsor
Xencor, Inc.
Target Recruit Count
154
Registration Number
NCT02924402
Locations
🇺🇸

The University of Chicago Medicine, Chicago, Illinois, United States

🇺🇸

Northside Hospital, Atlanta, Georgia, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

and more 20 locations

Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195

First Posted Date
2016-08-29
Last Posted Date
2017-07-11
Lead Sponsor
Xencor, Inc.
Target Recruit Count
57
Registration Number
NCT02881853
Locations
🇺🇸

ICON Early Phase Services, LLC, San Antonio, Texas, United States

XmAb5871 Bioavailability Study

Phase 1
Completed
Conditions
Interventions
First Posted Date
2016-08-15
Last Posted Date
2017-12-08
Lead Sponsor
Xencor, Inc.
Target Recruit Count
50
Registration Number
NCT02867098
Locations
🇺🇸

PAREXEL, Early Phase Clinical Unit-Los Angeles, Glendale, California, United States

PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

First Posted Date
2016-04-06
Last Posted Date
2022-03-08
Lead Sponsor
Xencor, Inc.
Target Recruit Count
120
Registration Number
NCT02730312
Locations
🇺🇸

Northside Hospital, Atlanta, Georgia, United States

🇺🇸

Mayo Clinic Jacksonville, Jacksonville, Florida, United States

🇺🇸

Swedish Cancer Institute, Seattle, Washington, United States

and more 6 locations
© Copyright 2024. All Rights Reserved by MedPath